Human papillomavirus vaccine TA-HPV - Xenova

Drug Profile

Human papillomavirus vaccine TA-HPV - Xenova

Alternative Names: TA-HPV

Latest Information Update: 14 Aug 2007

Price : $50

At a glance

  • Originator
  • Developer Xenova Group
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Vulvar intraepithelial neoplasia

Most Recent Events

  • 29 Jul 2004 Suspended - Phase-II for Cervical cancer in USA (Intradermal)
  • 29 Jul 2004 Suspended - Phase-II for Cervical cancer in United Kingdom (Intradermal)
  • 29 Jul 2004 Suspended - Phase-II for Cervical intraepithelial neoplasia in United Kingdom (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top